Vertex Pharmaceuticals
As on 01 Jan, 2026 | 02:29 IST
| Open | 451.75 |
| Previous Close | 453.74 |
| Beta | 0.09 |
| High | 455.92 |
| Low | 452.64 |
| TTM EPS See historical trend | 17.36(+3303.92% YoY) |
| 52 Week High | 519.68 |
| 52 Week Low | 362.97 |
| TTM PE See historical trend | 26.12(Low PE) |
| Mkt. Cap ($ Billion) | 117.13 |
| Dividend Yield | -- |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 457.86 |
| 10 | 455.82 |
| 20 | 452.19 |
| 50 | 435.88 |
| 100 | 415.11 |
| 200 | 440.85 |
Returns
| 1 Week | -1.26% | |
| 1 Month | 4.58% | |
| 3 Months | 15.78% | |
| YTD | 12.62% | |
| 1 Year | 12.62% | |
| 3 Years | 57.10% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| J&J | 206.95 | 0.02 | 498.78 | 19.94 | 10.38 | 2.83 | 215.04/141.30 | 0.14 | Very Bullish |
| AbbVie | 228.49 | -0.54 | 403.74 | 24.18 | 9.45 | 3.49 | 244.80/164.59 | 0.34 | Very Bullish |
| Merck | 105.26 | -0.75 | 266.69 | 12.17 | 8.65 | 3.86 | 107.59/73.35 | 0.65 | Very Bullish |
| Amgen | 327.31 | -0.42 | 175.96 | 14.97 | 21.87 | 3.33 | 346.38/257.13 | -5.24 | Bullish |
| Gilead Sciences | 122.74 | -0.36 | 153.07 | 14.99 | 8.19 | 2.83 | 128.68/88.59 | -2.39 | Neutral |
Market news
- Dow, S&P 500 close at record highs as Santa rally startsDecember 25, 2025 8:04 AM
- Stocks rise with tech boost, yen weakens after Japan rate hikeDecember 20, 2025 12:20 PM
- Wall Street ends lower; fears of AI bubble and inflation send investors awayDecember 13, 2025 9:01 AM
- Wall Street closes with slight gains as data keeps Fed cut expectations on trackDecember 6, 2025 8:34 AM
About the company
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.